2022
Exports
$90.3kWorld Rnk 133 / 208
Flag Rnk 273 / 763
2022
PRODUCT COMPLEXITY IN Vaccines, blood, antisera, toxins and cultures
1.38Rnk 75 / 1025
2022
Imports
$65.3MWorld Rnk 116 / 225
Flag Rnk 23 / 1153
2022
ECONOMIC COMPLEXITY of Zimbabwe
-0.74Rnk 99 / 133

About

Exports In 2022, Zimbabwe exported $90.3k in Vaccines, blood, antisera, toxins and cultures, making it the 133rd largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 273rd most exported product in Zimbabwe. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Zimbabwe are: Namibia ($41k), France ($16.5k), Zambia ($8.69k), Spain ($7.61k), and India ($5.59k).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Zimbabwe between 2021 and 2022 were Namibia ($40.8k), France ($16.3k), and Spain ($7.5k).

Imports In 2022, Zimbabwe imported $65.3M in Vaccines, blood, antisera, toxins and cultures, becoming the 116th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 23rd most imported product in Zimbabwe. Zimbabwe imports Vaccines, blood, antisera, toxins and cultures primarily from: Hong Kong ($20.7M), China ($17.4M), India ($8.24M), South Africa ($5.17M), and Belgium ($4.78M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Zimbabwe between 2021 and 2022 were India ($3.28M), Japan ($687k), and Singapore ($372k).

Latest Trends

Oct 2024

Subnational Monthly Trade

View
Flow
Y-AXIS SCALE

For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.

The following visualization shows the latest trends on Vaccines, blood, antisera, toxins and cultures. Countries are shown based on data availability.

* Using January 2020 exchange rates when trade data is reported in local currency.

Explore Latest Trends

Subscribe today to OEC pro and access the latest data

Sign Up

Historical Data

Trade Balance

Color
EXPORTS (2022)$90.3k
IMPORTS (2022)$65.3M
NET TRADE (2022)-$65.2M

In 2022, Zimbabwe exported $90.3k in Vaccines, blood, antisera, toxins and cultures. The main destinations of Zimbabwe exports on Vaccines, blood, antisera, toxins and cultures were Namibia ($41k), France ($16.5k), Zambia ($8.69k), Spain ($7.61k), and India ($5.59k).

In 2022, Zimbabwe imported $65.3M in Vaccines, blood, antisera, toxins and cultures, mainly from Hong Kong ($20.7M), China ($17.4M), India ($8.24M), South Africa ($5.17M), and Belgium ($4.78M).

Explore Visualizations

Export Destinations (2022)

Import Origins (2022)

Market Growth

Flow
THE FASTEST GROWING Vaccines, blood, antisera, toxins and cultures EXPORT MARKETS FOR Zimbabwe WERE (2021 - 2022):
Namibia$40.8k (26.9k%)
France$16.3k (14k%)
Spain$7.5k (7.36k%)
THE FASTEST DECLINING MARKETS FOR THE EXPORT OF Vaccines, blood, antisera, toxins and cultures BY Zimbabwe WERE (2021 - 2022):
United Kingdom-$16.3k (-99.6%)
Mozambique-$9.81k (-100%)
South Africa-$7.36k (-76.4%)

Change in Exports by Market (2021 - 2022)

Market Concentration

View
Flow
Type
In 2022, Zimbabwe's main exporting competitors in Vaccines, blood, antisera, toxins and cultures were:
In 2022, Zimbabwe's main importing competitors in Vaccines, blood, antisera, toxins and cultures were:

Explore Visualizations

Trade Value of Vaccines, blood, antisera, toxins and cultures by Exporters

Potential Exports

Potential Exports

Flow
View
TOP EXPORT POTENTIALFrance+ $54.8k
TOP IMPORT POTENTIALBelgium+ $4.54M

Vaccines, blood, antisera, toxins and cultures’s highest export potential is France. With an export gap of $54.8k.   Vaccines, blood, antisera, toxins and cultures’s highest import potential is Belgium with an import gap of $4.54M.

See methodology.

Subscribe today to OEC pro and access the latest data

Sign Up

Have questions, comments, or concerns?
Send us an e-mail: support@oec.world
Follow @OECtoday on
Created, Designed, and Developed by:
In collaboration with